Validation of the updated PRECISE-DAPT cancer score in an Asian population cohort

Patients with cancer have a higher risk of heart attack and bleeding compared to patients without cancer. This problem is further exacerbated when patients with cancer undergo stenting for blockages to the blood vessels of their heart, as this necessitates an extended period of blood-thinning medications, further increasing the risk of bleeding. However, cancer has not been included in any standardized bleeding risk scores used presently for treatment individualisation. Recently, our collaborators from the United Kingdom (UK) have incorporated cancer into the well-established PRECISE-DAPT scoring for evaluating bleeding risk, and have shown that the modified score was better at identifying patients with cancer to be of higher bleeding risk within the UK population. The aim of this study is to validate this modified risk score externally within our Asian population to better risk stratify the bleeding risk of patients with cancer who have undergone stenting.